UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 20, 2014

Supernus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
Incorporation)

Registrant’s telephone number, including area code:  (301) 838-2500

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02              Other Events

On February 25, 2014, Supernus issued a press release announcing that it expects to report financial results for the fourth quarter and full year ending December 31, 2013 after the market closes on March 12, 2014, and will hold a conference call and webcast on that date to review the 2013 financial results and to provide a business update.  A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 8.01              Other Events.

On February 20, 2014, Supernus issued a press release announcing that the company’s management will provide a business update on March 3, 2014 at the Cowen and Company Healthcare Conference in Boston, Massachusetts.  A copy of the press release is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.

Item 9.01              Financial Statements and Exhibits.

(d)           Exhibits

The following document is furnished as Exhibit pursuant to Item 2.02 hereof:

Exhibit 99.1 — Press Release Dated February 25, 2014 of the Company.

The following document is furnished as Exhibit pursuant to Item 8.01 hereof:

Exhibit 99.2 — Press Release Dated February 20, 2014 of the Company.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

3

EXHIBIT INDEX

4

EXHIBIT 99.1

FOR IMMEDIATE RELEASE

Supernus to Host Fourth Quarter and Full Year 2013 Earnings Conference Call

Rockville, MD, February 25, 2014 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company expects to report fourth quarter and full year 2013 financial results after the market closes Wednesday, March 12, 2014.  CEO, Jack Khattar, and CFO, Greg Patrick, will be hosting a conference call on Thursday, March 13, 2014 at 9:00 AM Eastern Time, to discuss 2013 financial results and to provide a business update.

A live webcast will be available at www.supernus.com.  Following the live call, a replay will be available on the Company’s website under ‘Investor Info’.  The webcast will be archived on the Company’s website for 30 business days following the live call.

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Supernus Pharmaceuticals, Inc.
Jack A. Khattar, 301-838-2591
President and CEO
or
Gregory S. Patrick, 301-838-2591
Vice President and CFO
or
Investor Contact:
Cockrell Group, 877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com

EXHIBIT 99.2

FOR IMMEDIATE RELEASE

Supernus to Present at Cowen and Company Healthcare Conference in March

Rockville, MD, February 20, 2014 - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that the Company’s management will provide a business update on the Company at the Cowen and Company Healthcare Conference.

Presentation Date:  Monday, March 3

Time:  1:30pm ET

Place:  The Boston Marriott Copley Place Hotel, Boston, MA

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

Supernus Pharmaceuticals, Inc.
Jack A. Khattar, President and CEO
or
Gregory S. Patrick, Vice President and CFO
301-838-2591
or
Investor Contact:
Cockrell Group, 877-889-1972
investorrelations@thecockrellgroup.com
cockrellgroup.com